Shots:
- The US FDA has cleared NexEos Bio’s IND application to initiate a P-II/III clinical study of NTX-1024 ophthalmic solution for the treatment of vernal keratoconjunctivitis (VKC)
- The P-II/III study will evaluate the safety and efficacy of NTX-1024 in VKC, following positive results from an open-label investigator-initiated study showing improvements in symptoms and ocular inflammation with favorable tolerability
- NTX-1024 recently received US FDA Orphan Drug Designation for VKC; NexEos plans to initiate the P-II/III study in H2’26
Ref: Business Wire | Image: NexEos Bio | Press Release
Related News: Boehringer Ingelheim Secures US FDA’s EUA for NexGard and NexGard COMBO to Treat NWS
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
